Virpax Pharmaceuticals Files Provisional Patent Application For Intranasal Delivery
Portfolio Pulse from Benzinga Newsdesk
Virpax Pharmaceuticals has filed a new provisional patent application for its product candidate Envelta, which uses Molecular Envelope Technology (MET) for intranasal delivery of Enkephalin for severe cancer and non-cancer pain. The MET was developed by Nanomerics Ltd., which has licensed its technology to Virpax. The development program for Envelta is being funded almost exclusively through a Cooperative Research and Development Agreement with the National Center for Advancing Translational Sciences.
July 13, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Virpax's new patent application for Envelta could strengthen its product portfolio and potentially lead to a competitive advantage in the pain management market.
The filing of a new patent application indicates that Virpax is actively developing its product portfolio. If the patent is granted, it could provide Virpax with a competitive advantage by protecting its technology from being used by competitors. This could potentially lead to increased market share and revenues for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100